Femara 2.5 Mg 30 Tablets
Brand : novartis pharmaceuticals
Requires Prescription (YES/NO)
How it works
Letrozole is a nonsteroidal competitive inhibitor of the aromatase enzyme system; it inhibits the conversion of androgens to estrogens. In adult nontumor- and tumor-bearing female animals, letrozole is as effective as ovariectomy in reducing uterine weight, elevating serum LH, and causing the regression of estrogen-dependent tumors. In contrast to ovariectomy, treatment with letrozole does not lead to an increase in serum FSH. Letrozole selectively inhibits gonadal steroidogenesis but has no significant effect on adrenal mineralocorticoid or glucocorticoid synthesis.
USAGE AND SAFETY
Common or very common: Abdominal pain ,alopecia ,anorexia,appetite increase, arthralgia,bone fracture, Constipation, depression, diarrhea, dizziness, dry skin, dyspepsia, fatigue, headache, hot flushes, hypercholesterolaemia, hypertension, increased sweating, musculoskeletal pain, nausea, osteoporosis, peripheral oedema, rash, vaginal bleeding,vomiting, weight changes. Uncommon: Anxiety, arthritis, blurred vision, breast pain, cardiac events, cataract, cerebrovascular events, cough, Dysaesthesia, dyspnea, eye irritation, general oedema, insomnia, leucopenia, memory impairment, mucosal Dryness, palpitation, pruritus, pyrexia, stomatitis, tachycardia, taste disturbance, thrombophlebitis, tumour pain, urinary frequency,urinary-tract infection,urticaria. vaginal discharge. Rare: Arterial thrombosis . pulmonary embolism. Frequency not known: Hepatitis ,toxic epidermal necrolysis.
Tamoxifen , Cimetidine , Warfarin .
It is indicated in : • First-line treatment in postmenopausal women with hormone-dependent advanced breast cancer.• Adjuvant treatment of oestrogen receptor positive invasive early breast cancer in postmenopausal women.• Advanced breast cancer in postmenopausal women (naturally or artificially induced menopause) in whom other antiestrogen therapy has failed.• Extended adjuvant treatment of hormone-dependent invasive breast cancer in postmenopausal women who have received standard adjuvant tamoxifen therapy for 5 years.• Neo adjuvant treatment in postmenopausal women with localized hormone receptor positive, human epidermal growth factor-2 negative breast cancer where chemotherapy is not suitable and surgery not yet indicated.
When not to Use
Known hypersensitivity to the active substance, or to any of the excipients. Not indicated for premenopausal women. Letrozole is contraindicated during breast-feeding. Letrozole is contraindicated during pregnancy. Letrozole can cause fetal harm.
Because fatigue, dizziness, and somnolence have been reported with the use of Letrozole, caution is advised when driving or using machinery until it is known how the patient reacts to Letrozole use.
Use of Letrozole may cause decreases in bone mineral density (BMD). Lets is a potent oestrogen-lowering agent. Women with a history of osteoporosis and/or fractures, or who are at increased risk of osteoporosis, should have their bone mineral density formally assessed prior to the commencement of adjuvant and extended adjuvant treatment and monitored during and following treatment with letrozole is required for patients with renal insufficiency with creatinine clearance =10 ml/min. Caution is there if creatinine clearance less than 10ml/minute.
Consideration should be given to monitoring serum cholesterol.
Subjects with cirrhosis and severe hepatic impairment who were dosed with 2.5 mg of Letrozole experienced approximately twice the exposure to Letrozole as healthy volunteers with normal liver function. Therefore, a dose reduction is recommended for this patient population.
Always consult your physician before using any medicine.
Store this medicine at room temperature, away from direct light and heat.